Currently out of the existing stock ratings of Carter Gould, 175 are a BUY (54.18%), 118 are a HOLD (36.53%), 30 are a SELL (9.29%).

Carter Gould

Work Performance Price Targets & Ratings Chart

Analyst Carter Gould, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 77.03% that have a potential upside of 30.34% achieved within 285 days. Previously, Carter Gould worked at BARCLAYS.

Carter Gould’s has documented 645 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on ABBV, AbbVie at 06-Jul-2026.

Wall Street Analyst Carter Gould

Analyst best performing recommendations are on APLT (APPLIED THERAPEUTICS).
The best stock recommendation documented was for APLT (APPLIED THERAPEUTICS) at 3/21/2022. The price target of $2.5 was fulfilled within 3 days with a profit of $0.67 (36.61%) receiving and performance score of 122.04.

Average potential price target upside

of $96.29 (18.93%) on LLY (ELI LILLY AND COMPANY).
of $89.91 (15.56%) on REGN (REGENERON PHARMACEUTICALS).
of $64.66 (20.41%) on VRTX (VERTEX PHARMACEUTICALS).

ABBV AbbVie ALLK Allakos AMGN Amgen APLT Applied Therapeutics BIIB Biogen BMY Bristol-Myers Squibb Company CYTK Cytokinetics GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany NBIX Neurocrine Biosciences PFE Pfizer REGN Regeneron Pharmaceuticals TVTX Travere Therapeutics XLRN Acceleron Pharma GOSS Gossamer Bio RETA Reata Pharmaceuticals ALEC Alector CELG Celgene MTEM Molecular Templates VOR Vor Biopharma ACLX Arcellx ESPR Esperion Therapeutics INCY yte VRTX Vertex Pharmaceuticals SKIL Skillsoft Corp. NUVL Nuvalent PCVX Vaxcyte ACIU AC Immune Ltd BTAI BioXcel Therapeutics MT ArcelorMittal SA ADR CE Celanese

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gary Nachman (RAYMOND JAMES)